A Phase 2 interventional study of EDP-323 Dose Regimen 1 and EDP-323 Dose Regimen 2 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc — 1 open to participants now, 1 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Enanta Pharmaceuticals, Inc.
Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 4th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 2, and was the 10th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc is open now, in 1 country. Recruiting first, the newest first:
Enanta Pharmaceuticals, Inc · Sites in Thailand
Ages 28 days–36 mo
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482657Enanta Pharmaceuticals, IncA Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take EDP-323 Dose 1 orally for 5 days
Drug: EDP-323 Dose Regimen 1
Subjects will take EDP-323 Dose 2 orally for 5 days
Drug: EDP-323 Dose Regimen 2
Subjects will take matching placebo orally for 5 days
Drug: Placebo
EDP-323 capsule
EDP-323 capsule
Placebo capsule
Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC)
Measured by qRT-PCR in nasal samples.
Time frame: Day 1 to Day 12
qRT-PCR: RSV Peak Viral Load (VLPEAK)
Measured by qRT-PCR in nasal samples.
Time frame: Day 1 to Day 12
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK
Measured by qRT-PCR in nasal samples.
Time frame: Day 1 to Day 12
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity
The time from the assessment at the time of the first dose of IMP to qRT-viral load negativity was analyzed using the Kaplan-Meier method. Viral load negativity was reached at the first time when the viral load was undetectable (\< lower limit of detection \[LLOD\]) by qRT-PCR, after which no further detectable assessment appeared. Measured by qRT-PCR in nasal samples.
Time frame: Day 1 to Day 12
qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load
Time to first negative slope = time of the timepoint after which there are two consecutive declines in viral load - time of the nearest viral load assessment to the first dose of IMP. Measured by qRT-PCR in nasal samples.
Time frame: Day 1 to Day 12
qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 High Dose
Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 high dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.
Time frame: Up to Day 16
qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 Low Dose
Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 low dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.
Time frame: Up to Day 16
Viral Culture: RSV VL-AUC
Measured by viral culture (plaque assay) in nasal samples.
Time frame: Day 1 to Day 12
Viral Culture: RSV VLPEAK
Measured by viral culture (plaque assay) in nasal samples.
Time frame: Day 1 to Day 12
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK
Measured by viral culture (plaque assay) in nasal samples.
Time frame: Day 1 to Day 12
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity
Measured by viral culture (plaque assay) in nasal samples.
Time frame: Day 1 to Day 12
Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load
Measured by viral culture (plaque assay) in nasal samples.
Time frame: Day 1 to Day 12
Viral Culture: RSV Viral Load Clearance Rate
Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. A negative slope indicated that the viral load decreased over time. Measured by viral culture in nasal samples.
Time frame: Up to Day 16
Area Under the Total Symptom Score (TSS)-Time Curve (TSS-AUC)
An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome. The calculation of the TSS-AUC was performed on the TSS measured 3 times a day using the trapezoidal summation rule based on actual time intervals in hours.
Time frame: Day 1 to Day 12
Peak TSS
Defined as the highest recorded value of TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.
Time frame: Day 1 to Day 12
Time to Peak TSS
Time to peak TSS = time of peak TSS - time of the nearest TSS assessment to the first dose of IMP. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.
Time frame: Day 1 to Day 12
Time to Resolution From Peak TSS
Time to resolution from peak TSS = time of the first 24-hour symptom-free time point - time of peak TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.
Time frame: Day 1 to Day 12
Total Weight of Nasal Discharge (Mucus) Produced
Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).
Time frame: Day 1 to Day 12
Total Number of Tissues Used
Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).
Time frame: Day 1 to Day 12
Maximum Plasma Concentration (Cmax)
Plasma pharmacokinetic (PK) parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, below the limit of quantification (BQL) values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Time to Cmax (Tmax)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Terminal Half-life (t1/2)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Apparent Systemic Clearance at Steady-state (CLss/F)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Terminal Elimination Rate Constant (λz)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Apparent Volume of Distribution at Steady-state (Vss/F)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose), Day 2 pre-dose, Day 3 pre-dose, Day 4 pre-dose, Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Plasma Concentration at 12 Hours (C12h) and 24 Hours (C24h)
In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: First Dose: Day 1, 12 and 24 hours post-dose; Last Dose: Day 5, 12 and 24 hours post-dose
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: First Dose: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 15 hours post-dose) and Day 2 pre-dose; Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Area Under the Concentration-time Curve Over the Dosing Interval (AUC0-tau)
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
Time frame: Last Dose: Day 5 (pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, and 72 hours post-dose)
Number of Participants With Adverse Events (AEs) up to Discharge
An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event
Time frame: Day -2 to Day 12
Number of Participants With Treatment-emergent Adverse Events
An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event
Time frame: Day 1 to Day 28
A total of 142 participants were enrolled and inoculated with challenge virus (Respiratory Syncytial Virus \[RSV\]-A Memphis 37b) of which 141 participants were randomized 1:1:1 into one of three treatment groups to receive EDP-323 (at two different doses) or placebo at one site in the United Kingdom between November 2023 and July 2024.
| Milestone | EDP-323 High Dose | EDP-323 Low Dose | Placebo | Enrolled But Not Randomized |
|---|---|---|---|---|
| Started | 47 | 47 | 47 | 1 |
| Completed | 47 | 47 | 46 | 0 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
Measured by qRT-PCR in nasal samples.
| log10 copies/mL*hours | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) | 99.05 ± 133.325 | 82.28 ± 158.033 | 657.45 ± 396.743 |
Measured by qRT-PCR in nasal samples.
| log10 copies/mL | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| qRT-PCR: RSV Peak Viral Load (VLPEAK) | 2.52 ± 2.173 | 1.99 ± 2.711 | 6.48 ± 2.311 |
Measured by qRT-PCR in nasal samples.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK | 2.89 ± 2.922 | 3.12 ± 3.113 | 3.12 ± 1.555 |
The time from the assessment at the time of the first dose of IMP to qRT-viral load negativity was analyzed using the Kaplan-Meier method. Viral load negativity was reached at the first time when the viral load was undetectable (\< lower limit of detection \[LLOD\]) by qRT-PCR, after which no further detectable assessment appeared. Measured by qRT-PCR in nasal samples.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity | 2.3 (1.0 to 6.5) | 1.5 (0.5 to 6.0) | 8.5 (6.5 to NA) |
Time to first negative slope = time of the timepoint after which there are two consecutive declines in viral load - time of the nearest viral load assessment to the first dose of IMP. Measured by qRT-PCR in nasal samples.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| qRT-PCR: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load | 0.77 ± 0.954 | 1.33 ± 2.360 | 2.60 ± 1.632 |
Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 high dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.
| log10 copies/mL/day | EDP-323 High Dose | Placebo |
|---|---|---|
| qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 High Dose | -0.5650 (-0.7539 to -0.3761) | -1.3299 (-1.4775 to -1.1823) |
Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. The model was a distinct analysis for the EDP-323 low dose and placebo groups where the estimates for both groups are model-dependent and impacted by the overall model. A negative slope indicated that the viral load decreased over time. Measured by qRT-PCR in nasal samples.
| log10 copies/mL/day | EDP-323 Low Dose | Placebo |
|---|---|---|
| qRT-PCR: RSV Viral Load Clearance Rate - EDP-323 Low Dose | -0.5480 (-0.8182 to -0.2778) | -1.3298 (-1.4896 to -1.1699) |
Measured by viral culture (plaque assay) in nasal samples.
| log10 plaque-forming units (PFU)/mL*h | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Viral Culture: RSV VL-AUC | 3.82 ± 9.333 | 6.21 ± 15.448 | 227.04 ± 189.998 |
Measured by viral culture (plaque assay) in nasal samples.
| log10 PFU/mL | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Viral Culture: RSV VLPEAK | 0.04 ± 0.198 | 0.16 ± 0.569 | 3.45 ± 2.191 |
Measured by viral culture (plaque assay) in nasal samples.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV VLPEAK | 5.82 ± 2.980 | 5.78 ± 3.304 | 3.95 ± 2.290 |
Measured by viral culture (plaque assay) in nasal samples.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to RSV Viral Load Negativity | 0.5 (0.5 to NA) | 0.5 (0.5 to NA) | 4.5 (4.5 to 5.5) |
Measured by viral culture (plaque assay) in nasal samples.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Viral Culture: Time From the Assessment at the Time of the First Dose of IMP to First Negative Slope of RSV Viral Load | 0.00 ± 0.000 | 0.00 ± 0.000 | 2.92 ± 1.739 |
Calculated as the slope of the RSV viral load over time from time of RSV VLPEAK to 1, 2, 3, and 4 days later. Estimates for fixed effects of a mixed linear model, modeling the viral load from peak up to the 4 following days, with time from VLPEAK, group and interaction between time and group as fixed effects and a random intercept within each participant. A negative slope indicated that the viral load decreased over time. Measured by viral culture in nasal samples.
| log10 PFU/mL/day | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Viral Culture: RSV Viral Load Clearance Rate | -0.1336 (-0.7642 to 0.4970) | -0.2565 (-0.6990 to 0.1861) | -1.1124 (-1.2522 to -0.9727) |
An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome. The calculation of the TSS-AUC was performed on the TSS measured 3 times a day using the trapezoidal summation rule based on actual time intervals in hours.
| score*hours | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Area Under the Total Symptom Score (TSS)-Time Curve (TSS-AUC) | 127.31 ± 149.221 | 82.67 ± 100.412 | 369.10 ± 330.397 |
Defined as the highest recorded value of TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.
| score on a scale | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Peak TSS | 2.65 ± 1.765 | 2.35 ± 2.673 | 5.77 ± 4.439 |
Time to peak TSS = time of peak TSS - time of the nearest TSS assessment to the first dose of IMP. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Time to Peak TSS | 2.00 ± 2.403 | 2.84 ± 3.125 | 3.36 ± 2.065 |
Time to resolution from peak TSS = time of the first 24-hour symptom-free time point - time of peak TSS. An individual TSS (10-items) was derived at each assessment of the diary card as the sum of the scores given to the 10 following symptoms on that symptom score card, giving a score between 0 and 3: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise/Tiredness * Headache * Muscle and/or Joint Ache * Cough * Shortness of breath TSS ranged from 0 to 30 with higher TSS indicating a higher disease burden and thus a worse outcome.
| days | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Time to Resolution From Peak TSS | 2.16 ± 1.922 | 2.58 ± 2.415 | 2.93 ± 1.789 |
Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).
| grams | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Total Weight of Nasal Discharge (Mucus) Produced | 6.12 ± 6.564 | 9.49 ± 20.537 | 16.44 ± 22.152 |
Each participant was given pre-weighed packets of paper tissues. Participants were asked to place single tissues used for nose blowing or sneezing into a specified collection bag (for that participant only).
| tissues | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Total Number of Tissues Used | 17.62 ± 23.329 | 16.22 ± 21.457 | 28.79 ± 27.580 |
Plasma pharmacokinetic (PK) parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, below the limit of quantification (BQL) values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| ng/mL | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| First Dose: EDP-323 | 1358.47 ± 590.191 | 1453.70 ± 627.552 |
| Last Dose: EDP-323 | 1703.09 ± 746.730 | 759.38 ± 322.938 |
| First Dose: EP-038725 | 1225.02 ± 753.882 | 1501.55 ± 776.020 |
| Last Dose: EP-038725 | 1294.19 ± 772.921 | 381.94 ± 266.839 |
| First Dose: EP-039082 | 5.40 ± 5.265 | 6.59 ± 4.923 |
| Last Dose: EP-039082 | 6.41 ± 5.131 | 1.40 ± 1.346 |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| hours | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| First Dose: EDP-323 | 3.98 (1.0 to 10.2) | 3.92 (1.9 to 9.9) |
| Last Dose: EDP-323 | 4.82 (2.0 to 9.9) | 4.10 (1.0 to 10.3) |
| First Dose: EP-038725 | 3.97 (1.9 to 10.2) | 3.85 (1.9 to 9.9) |
| Last Dose: EP-038725 | 4.92 (2.0 to 9.9) | 3.98 (1.0 to 10.0) |
| First Dose: EP-039082 | 3.00 (0.0 to 9.9) | 2.97 (0.9 to 9.9) |
| Last Dose: EP-039082 | 3.82 (1.0 to 9.9) | 2.00 (0.0 to 7.9) |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| hours | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| EDP-323 | 13.07 ± 4.793 | 12.55 ± 4.621 |
| EP-038725 | 16.56 ± 3.049 | 17.16 ± 3.103 |
| EP-039082 | 3.89 ± 1.346 | — |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| L/h | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| EDP-323 | 32.39 ± 13.648 | 24.51 ± 11.383 |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| per hour | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| EDP-323 | 0.06 ± 0.018 | 0.06 ± 0.019 |
| EP-038725 | 0.04 ± 0.009 | 0.04 ± 0.008 |
| EP-039082 | 0.17 ± 0.061 | — |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The plasma PK parameters were estimated from the concentration-time profiles. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| liters | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| EDP-323 | 569.26 ± 208.202 | 402.73 ± 143.305 |
In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| ng/mL | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| First Dose C12h: EDP-323 | 711.96 ± 265.557 | 756.02 ± 345.633 |
| First Dose C24h: EDP-323 | 351.45 ± 166.086 | 368.54 ± 216.140 |
| Last Dose C12h: EDP-323 | 935.04 ± 318.005 | 423.38 ± 203.294 |
| Last Dose C24h: EDP-323 | 493.16 ± 250.229 | 220.69 ± 141.715 |
| First Dose C12h: EP-038725 | 189.71 ± 94.962 | 221.48 ± 162.256 |
| First Dose C24h: EP-038725 | 52.47 ± 27.362 | 56.57 ± 23.845 |
| Last Dose C12h: EP-038725 | 281.01 ± 168.564 | 78.22 ± 39.056 |
| Last Dose C24h: EP-038725 | 96.78 ± 59.546 | 30.29 ± 14.620 |
| First Dose C12h: EP-039082 | 1.28 ± 0.493 | 1.44 ± 0.775 |
| First Dose C24h: EP-039082 | 1.00 ± 0.000 | 1.01 ± 0.041 |
| Last Dose C12h: EP-039082 | 1.60 ± 0.739 | 1.00 ± 0.014 |
| Last Dose C24h: EP-039082 | 1.04 ± 0.166 | 1.00 ± 0.000 |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| h*ng/mL | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| First Dose: EDP-323 | 15626.46 ± 5982.746 | 16703.77 ± 7268.939 |
| Last Dose: EDP-323 | 31084.37 ± 13945.732 | 13816.76 ± 7801.297 |
| First Dose: EP-038725 | 7181.42 ± 3848.438 | 8319.19 ± 3563.734 |
| Last Dose: EP-038725 | 10814.63 ± 5619.005 | 3174.73 ± 1641.754 |
| First Dose: EP-039082 | 26.11 ± 21.928 | 31.34 ± 28.251 |
| Last Dose: EP-039082 | 35.35 ± 28.171 | 4.77 ± 4.119 |
Plasma PK parameters for EDP-323 and metabolites (EP-038725 and EP-039082) were estimated using non-compartmental methods. The AUCs were calculated using linear up/log down method. In estimating the PK parameters, BQL values were set to zero. Actual sampling times, rather than scheduled sampling times, were used in all computations involving sampling times. If the actual time or dose time was missing, the scheduled time could be substituted in order to calculate the PK parameter. In case of an actual sampling time deviating by \>20% from the scheduled (nominal) time, this plasma concentration was excluded from descriptive statistics in the plasma concentration-time table.
| h*ng/mL | EDP-323 High Dose | EDP-323 Low Dose |
|---|---|---|
| Last Dose: EDP-323 | 21585.30 ± 7915.479 | 9653.80 ± 4245.794 |
| Last Dose: EP-038725 | 8944.82 ± 4528.012 | 2588.19 ± 1379.765 |
| Last Dose: EP-039082 | 48.21 ± 26.600 | 7.31 ± 10.464 |
An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event
| Participants | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Any AE | 13 | 15 | 15 |
| Any SAE | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical (investigational or non-investigation) product. An AE does not necessarily have a causal relationship with the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death * Was life threatening * Required inpatient hospitalization or prolongation of existing hospitalization * Resulted in persistent disability/incapacity * Was a congenital anomaly/birth defect * Was an important medical event
| Participants | EDP-323 High Dose | EDP-323 Low Dose | Placebo |
|---|---|---|---|
| Any TEAEs | 11 | 14 | 13 |
| Any Treatment-emergent SAEs | 0 | 0 | 0 |
Collected over All-cause mortality: Day -2 to Day 28; all adverse events: Day -2 to Day 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EDP-323 High Dose | 0/47 (0%) | 0/47 (0%) | 13/47 (27.7%) |
| EDP-323 Low Dose | 0/47 (0%) | 0/47 (0%) | 15/47 (31.9%) |
| Placebo | 0/47 (0%) | 0/47 (0%) | 15/47 (31.9%) |
| Enrolled But Not Randomized | 0/1 (0%) | — | — |
| Event | EDP-323 High Dose | EDP-323 Low Dose | Placebo | Enrolled But Not Randomized |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/47 | 3/47 | 1/47 | — |
| Viral upper respiratory tract infectionInfections and infestations | 1/47 | 2/47 | 1/47 | — |
| HeadacheNervous system disorders | 1/47 | 1/47 | 2/47 | — |
| PresyncopeNervous system disorders | 2/47 | 0/47 | 1/47 | — |
| Aspartate aminotransferase increasedInvestigations | 0/47 | 0/47 | 2/47 | — |
| Blood creatine phosphokinase increasedInvestigations | 0/47 | 0/47 | 2/47 | — |
| Breast abscessInfections and infestations | 1/47 | 0/47 | 0/47 | — |
| EpididymitisInfections and infestations | 1/47 | 0/47 | 0/47 | — |
| ParaesthesiaNervous system disorders | 1/47 | 0/47 | 0/47 | — |
| Sensory disturbanceNervous system disorders | 0/47 | 0/47 | 1/47 | — |
Safety Analysis Set (Treated Participants): All participants having received challenge virus and investigational medicinal product (IMP).
| Age, Continuous(years) | EDP-323 High Dose | EDP-323 Low Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 29.09 ± 6.372 | 27.62 ± 5.980 | 27.91 ± 6.223 | 28.21 ± 6.182 |
| Sex: Female, Male(Participants) | EDP-323 High Dose | EDP-323 Low Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 15 | 17 | 19 | 51 |
| Male | 32 | 30 | 28 | 90 |
| Race/Ethnicity, Customized(Participants) | EDP-323 High Dose | EDP-323 Low Dose | Placebo | Total |
|---|---|---|---|---|
| White | 39 | 35 | 38 | 112 |
| Black or African American | 3 | 7 | 5 | 15 |
| Asian | 2 | 3 | 1 | 6 |
| Other | 3 | 2 | 3 | 8 |
| Race/Ethnicity, Customized(Participants) | EDP-323 High Dose | EDP-323 Low Dose | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 4 |
| Not Hispanic or Latino | 46 | 45 | 46 | 137 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2023 to primary completion in Jun 2024, 6 months.
Results were first posted in Oct 2025, 1 year 3 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 6 months is below that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-323
Respiratory Syncytial Virus Infections →